Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet

Stock News10-24

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. ("Shon Pharmaceutical"), has received a "Notice of Drug Supplement Application Approval" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127558805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 15:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127558805","market":"sh","top_or_hot":-1,"title":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-24 15:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"","article_id":"1127558805","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127558805","pubTimestamp":1761291737,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","BK0175":"白马股","BK0099":"上海本地重组","BK0097":"医药电商","BK0028":"国家队","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","BK0012":"证金概念","BK0196":"行业龙头","02607":"上海医药","BK0187":"一线龙头"},"translate_title":"上海医药控股股份有限公司（601607.SH）子公司成为氨磺必利口服分散片上市许可持有人","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127558805","isCrawlerRequest":true}